Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

[Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer].

Rousset-Jablonski C, Selle F, Adda-Herzog E, Planchamp F, Selleret L, Pomel C, Chabbert-Buffet N, Daraï E, Pautier P, Trémollières F, Guyon F, Rouzier R, Laurence V, Chopin N, Faure-Conter C, Bentivegna E, Vacher-Lavenu MC, Lhomme C, Floquet A, Treilleux I, Lecuru F, Gouy S, Kalbacher E, Genestie C, de la Motte Rouge T, Ferron G, Devouassoux-Shisheboran M, Kurtz JE, Namer M, Joly F, Pujade-Lauraine E, Grynberg M, Querleu D, Morice P, Gompel A, Ray-Coquard I.

Bull Cancer. 2018 Feb 1. pii: S0007-4551(17)30385-5. doi: 10.1016/j.bulcan.2017.10.032. [Epub ahead of print] Review. French.

PMID:
29397916
2.

Breast cancer targeting through inhibition of the endoplasmic reticulum-based apoptosis regulator Nrh/BCL2L10.

Nougarede A, Popgeorgiev N, Kassem L, Omarjee S, Borel S, Mikaelian I, Lopez J, Gadet R, Marcillat O, Treilleux I, Villoutreix BO, Rimokh R, Gillet G.

Cancer Res. 2018 Jan 12. pii: canres.0846.2017. doi: 10.1158/0008-5472.CAN-17-0846. [Epub ahead of print]

PMID:
29330143
3.

Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration.

Small M, Treilleux I, Couillault C, Pissaloux D, Picard G, Paindavoine S, Attignon V, Wang Q, Rogemond V, Lay S, Ray-Coquard I, Pfisterer J, Joly F, Du Bois A, Psimaras D, Bendriss-Vermare N, Caux C, Dubois B, Honnorat J, Desestret V.

Acta Neuropathol. 2018 Jan 3. doi: 10.1007/s00401-017-1802-y. [Epub ahead of print]

PMID:
29299667
4.

Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma.

Dantas-Barbosa C, Lesluyes T, Loarer FL, Chibon F, Treilleux I, Coindre JM, Meeus P, Brahmi M, Bally O, Ray-Coquard I, Sunyach MP, Cesne AL, Mir O, Bonvalot S, Toulmonde M, Italiano A, Saintigny P, Jean-Denis M, Ducimetiere F, Ranchere D, El Sayadi H, Alberti L, Blay JY.

Br J Cancer. 2017 Dec 5;117(12):1787-1797. doi: 10.1038/bjc.2017.354. Epub 2017 Oct 12.

5.

Acinar-to-Ductal Metaplasia Induced by Transforming Growth Factor Beta Facilitates KRASG12D-driven Pancreatic Tumorigenesis.

Chuvin N, Vincent DF, Pommier RM, Alcaraz LB, Gout J, Caligaris C, Yacoub K, Cardot V, Roger E, Kaniewski B, Martel S, Cintas C, Goddard-Léon S, Colombe A, Valantin J, Gadot N, Servoz E, Morton J, Goddard I, Couvelard A, Rebours V, Guillermet J, Sansom OJ, Treilleux I, Valcourt U, Sentis S, Dubus P, Bartholin L.

Cell Mol Gastroenterol Hepatol. 2017 May 31;4(2):263-282. doi: 10.1016/j.jcmgh.2017.05.005. eCollection 2017 Sep.

6.

Non-canonical NOTCH3 signalling limits tumour angiogenesis.

Lin S, Negulescu A, Bulusu S, Gibert B, Delcros JG, Ducarouge B, Rama N, Gadot N, Treilleux I, Saintigny P, Meurette O, Mehlen P.

Nat Commun. 2017 Jul 18;8:16074. doi: 10.1038/ncomms16074.

7.

Ephrin-B3 supports glioblastoma growth by inhibiting apoptosis induced by the dependence receptor EphA4.

Royet A, Broutier L, Coissieux MM, Malleval C, Gadot N, Maillet D, Gratadou-Hupon L, Bernet A, Nony P, Treilleux I, Honnorat J, Liebl D, Pelletier L, Berger F, Meyronet D, Castets M, Mehlen P.

Oncotarget. 2017 Apr 4;8(14):23750-23759. doi: 10.18632/oncotarget.16077.

8.

Networking for ovarian rare tumors: a significant breakthrough improving disease management.

Chiannilkulchai N, Pautier P, Genestie C, Bats AS, Vacher-Lavenu MC, Devouassoux-Shisheboran M, Treilleux I, Floquet A, Croce S, Ferron G, Mery E, Pomel C, Penault-Llorca F, Lefeuvre-Plesse C, Henno S, Leblanc E, Lemaire AS, Averous G, Kurtz JE, Ray-Coquard I.

Ann Oncol. 2017 Jun 1;28(6):1274-1279. doi: 10.1093/annonc/mdx099.

PMID:
28398524
9.

The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone.

Bellanger A, Donini CF, Vendrell JA, Lavaud J, Machuca-Gayet I, Ruel M, Vollaire J, Grisard E, Győrffy B, Bièche I, Peyruchaud O, Coll JL, Treilleux I, Maguer-Satta V, Josserand V, Cohen PA.

J Pathol. 2017 May;242(1):73-89. doi: 10.1002/path.4882. Epub 2017 Mar 27.

PMID:
28207159
10.

Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.

Heudel PE, Fabbro M, Roemer-Becuwe C, Kaminsky MC, Arnaud A, Joly F, Roche-Forestier S, Meunier J, Foa C, You B, Priou F, Tazi Y, Floquet A, Selle F, Berton-Rigaud D, Lesoin A, Kalbacher E, Lortholary A, Favier L, Treilleux I, Ray-Coquard I.

Br J Cancer. 2017 Jan;116(3):303-309. doi: 10.1038/bjc.2016.430. Epub 2017 Jan 10.

11.

The molecular mechanisms underlying the ERα-36-mediated signaling in breast cancer.

Omarjee S, Jacquemetton J, Poulard C, Rochel N, Dejaegere A, Chebaro Y, Treilleux I, Marangoni E, Corbo L, Romancer ML.

Oncogene. 2017 May 4;36(18):2503-2514. doi: 10.1038/onc.2016.415. Epub 2016 Dec 12.

12.

Long-term exposure to bisphenol A or benzo(a)pyrene alters the fate of human mammary epithelial stem cells in response to BMP2 and BMP4, by pre-activating BMP signaling.

Clément F, Xu X, Donini CF, Clément A, Omarjee S, Delay E, Treilleux I, Fervers B, Le Romancer M, Cohen PA, Maguer-Satta V.

Cell Death Differ. 2017 Jan;24(1):155-166. doi: 10.1038/cdd.2016.107. Epub 2016 Oct 14.

13.

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers.

Ferrari A, Vincent-Salomon A, Pivot X, Sertier AS, Thomas E, Tonon L, Boyault S, Mulugeta E, Treilleux I, MacGrogan G, Arnould L, Kielbassa J, Le Texier V, Blanché H, Deleuze JF, Jacquemier J, Mathieu MC, Penault-Llorca F, Bibeau F, Mariani O, Mannina C, Pierga JY, Trédan O, Bachelot T, Bonnefoi H, Romieu G, Fumoleau P, Delaloge S, Rios M, Ferrero JM, Tarpin C, Bouteille C, Calvo F, Gut IG, Gut M, Martin S, Nik-Zainal S, Stratton MR, Pauporté I, Saintigny P, Birnbaum D, Viari A, Thomas G.

Nat Commun. 2016 Jul 13;7:12222. doi: 10.1038/ncomms12222.

14.

Surgical Management of Benign and Borderline Phyllodes Tumors of the Breast.

Moutte A, Chopin N, Faure C, Beurrier F, Ho Quoc C, Guinaudeau F, Treilleux I, Carrabin N.

Breast J. 2016 Sep;22(5):547-52. doi: 10.1111/tbj.12623. Epub 2016 Jun 6.

PMID:
27265474
15.

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GK, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, van't Veer L, Tutt A, Knappskog S, Tan BK, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.

Nature. 2016 Jun 2;534(7605):47-54. doi: 10.1038/nature17676. Epub 2016 May 2.

16.

Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.

Azim HA, Kassem L, Treilleux I, Wang Q, El Enein MA, Anis SE, Bachelot T.

Transl Oncol. 2016 Apr;9(2):114-123. doi: 10.1016/j.tranon.2016.01.001.

17.

CSF IgA NMDAR antibodies are potential biomarkers for teratomas in anti-NMDAR encephalitis.

Desestret V, Chefdeville A, Viaccoz A, Bost C, Ducray F, Picard G, Rogemond V, Chaffois MO, Blanc C, Bardel C, Treilleux I, Pascual O, Antoine JC, Delattre JY, Honnorat J.

Neurol Neuroimmunol Neuroinflamm. 2015 Oct 29;2(6):e166. doi: 10.1212/NXI.0000000000000166. eCollection 2015 Dec.

18.

SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas.

Le Loarer F, Watson S, Pierron G, de Montpreville VT, Ballet S, Firmin N, Auguste A, Pissaloux D, Boyault S, Paindavoine S, Dechelotte PJ, Besse B, Vignaud JM, Brevet M, Fadel E, Richer W, Treilleux I, Masliah-Planchon J, Devouassoux-Shisheboran M, Zalcman G, Allory Y, Bourdeaut F, Thivolet-Bejui F, Ranchere-Vince D, Girard N, Lantuejoul S, Galateau-Sallé F, Coindre JM, Leary A, Delattre O, Blay JY, Tirode F.

Nat Genet. 2015 Oct;47(10):1200-5. doi: 10.1038/ng.3399. Epub 2015 Sep 7.

PMID:
26343384
19.

[Axillary lymph node metastases with an occult breast: About 16 cases from a cohort of 7770 patients].

Couder F, Schmitt C, Treilleux I, Tredan O, Faure C, Carrabin N, Beurrier F, Chopin N.

Gynecol Obstet Fertil. 2015 Sep;43(9):588-92. doi: 10.1016/j.gyobfe.2015.06.010. Epub 2015 Aug 6. French.

PMID:
26257298
20.

TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.

Kassem L, Deygas M, Fattet L, Lopez J, Goulvent T, Lavergne E, Chabaud S, Carrabin N, Chopin N, Bachelot T, Gillet G, Treilleux I, Rimokh R.

BMC Cancer. 2015 Jun 4;15:453. doi: 10.1186/s12885-015-1471-y.

21.

DICER1 and FOXL2 mutations in ovarian sex cord-stromal tumours: a GINECO Group study.

Goulvent T, Ray-Coquard I, Borel S, Haddad V, Devouassoux-Shisheboran M, Vacher-Lavenu MC, Pujade-Laurraine E, Savina A, Maillet D, Gillet G, Treilleux I, Rimokh R.

Histopathology. 2016 Jan;68(2):279-85. doi: 10.1111/his.12747. Epub 2015 Jul 21.

PMID:
26033501
22.

Role of JMJD6 in Breast Tumourigenesis.

Poulard C, Rambaud J, Lavergne E, Jacquemetton J, Renoir JM, Trédan O, Chabaud S, Treilleux I, Corbo L, Le Romancer M.

PLoS One. 2015 May 7;10(5):e0126181. doi: 10.1371/journal.pone.0126181. eCollection 2015.

23.

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.

Leyland-Jones B, Gray KP, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Harvey VJ, Neven P, Treilleux I, Rasmussen BB, Maibach R, Price KN, Coates AS, Goldhirsch A, Pagani O, Viale G, Rae JM, Regan MM.

Breast Cancer Res Treat. 2015 Jun;151(2):373-84. doi: 10.1007/s10549-015-3378-3. Epub 2015 May 3.

24.

[Postoperative morbidities after modified posterior pelvic exenteration for ovarian cancer].

Emin L, Meeus P, Beurrier F, Ferraioli D, Carrabin N, Ray-Coquard I, Treilleux I, Chopin N.

Gynecol Obstet Fertil. 2015 May;43(5):342-7. doi: 10.1016/j.gyobfe.2015.03.006. Epub 2015 Apr 18. French.

PMID:
25899113
25.

17β-estradiol inhibits spreading of metastatic cells from granulosa cell tumors through a non-genomic mechanism involving GPER1.

François CM, Wargnier R, Petit F, Goulvent T, Rimokh R, Treilleux I, Ray-Coquard I, Zazzu V, Cohen-Tannoudji J, Guigon CJ.

Carcinogenesis. 2015 May;36(5):564-73. doi: 10.1093/carcin/bgv041. Epub 2015 Mar 30.

26.

[New therapeutical strategies in metastatic hormone-dependent breast cancer].

Vilquin P, Cohen P, Maudelonde T, Tredan O, Treilleux I, Bachelot T, Heudel PE.

Bull Cancer. 2015 Apr;102(4):367-80. doi: 10.1016/j.bulcan.2015.02.013. Epub 2015 Mar 21. Review. French.

27.

Disequilibrium of BMP2 levels in the breast stem cell niche launches epithelial transformation by overamplifying BMPR1B cell response.

Chapellier M, Bachelard-Cascales E, Schmidt X, Clément F, Treilleux I, Delay E, Jammot A, Ménétrier-Caux C, Pochon G, Besançon R, Voeltzel T, Caron de Fromentel C, Caux C, Blay JY, Iggo R, Maguer-Satta V.

Stem Cell Reports. 2015 Feb 10;4(2):239-54. doi: 10.1016/j.stemcr.2014.12.007. Epub 2015 Jan 15.

28.

[Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France].

MacGrogan G, Mathieu MC, Poulet B, Penault-Llorca F, Vincent-Salomon A, Roger P, Treilleux I, Valent A, Antoine M, Becette V, Bor C, Brabencova E, Charafe-Jauffret E, Chenard MP, Dauplat MM, Delrée P, Devouassoux M, Fiche M, Fondrevelle ME, Fridman V, Garbar C, Genin P, Ghnassia JP, Haudebourg J, Laberge-Le Couteulx S, Loussouarn D, Maran-Gonzalez A, Marcy M, Michenet P, Sagan C, Trassard M, Verriele V, Arnould L, Lacroix-Triki M; GEFPICS.

Ann Pathol. 2014 Oct;34(5):366-72. doi: 10.1016/j.annpat.2014.08.017. Epub 2014 Sep 26. French.

PMID:
25439989
29.

[2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France].

Penault-Llorca F, Vincent-Salomon A, MacGrogan G, Roger P, Treilleux I, Valent A, Mathieu MC, Antoine M, Becette V, Bor C, Brabencova E, Charafe-Jauffret E, Chenard MP, Dauplat MM, Delrée P, Devouassoux M, Fiche M, Fondrevelle ME, Fridman V, Garbar C, Genin P, Ghnassia JP, Haudebourg J, Laberge-Le Couteulx S, Loussouarn D, Maran-Gonzalez A, Marcy M, Michenet P, Poulet B, Sagan C, Trassard M, Verriele V, Arnould L, Lacroix-Triki M; GEFPICS.

Ann Pathol. 2014 Oct;34(5):352-65. doi: 10.1016/j.annpat.2014.08.018. Epub 2014 Sep 26. French.

PMID:
25439988
30.

Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.

Treilleux I, Arnedos M, Cropet C, Wang Q, Ferrero JM, Abadie-Lacourtoisie S, Levy C, Legouffe E, Lortholary A, Pujade-Lauraine E, Bourcier AV, Eymard JC, Spaeth D, Bachelot T.

Ann Oncol. 2015 Jan;26(1):120-5. doi: 10.1093/annonc/mdu497. Epub 2014 Oct 31.

PMID:
25361980
31.

Gynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma.

Fujiwara H, Yokota H, Monk B, Treilleux I, Devouassoux-Shisheboran M, Davis A, Kim JW, Mahner S, Stany M, Pignata S, Ray-Coquard I, Fujiwara K.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S96-101. doi: 10.1097/IGC.0000000000000263. Review.

PMID:
25341589
32.

Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix.

Satoh T, Takei Y, Treilleux I, Devouassoux-Shisheboran M, Ledermann J, Viswanathan AN, Mahner S, Provencher DM, Mileshkin L, Åvall-Lundqvist E, Pautier P, Reed NS, Fujiwara K.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S102-8. doi: 10.1097/IGC.0000000000000262. Review.

PMID:
25341572
33.

A functional interplay between ZNF217 and estrogen receptor alpha exists in luminal breast cancers.

Nguyen NT, Vendrell JA, Poulard C, Győrffy B, Goddard-Léon S, Bièche I, Corbo L, Le Romancer M, Bachelot T, Treilleux I, Cohen PA.

Mol Oncol. 2014 Dec;8(8):1441-57. doi: 10.1016/j.molonc.2014.05.013. Epub 2014 Jun 10.

34.

Management of patients diagnosed with atypical ductal hyperplasia by vacuum-assisted core biopsy: a prospective assessment of the guidelines used at our institution.

Caplain A, Drouet Y, Peyron M, Peix M, Faure C, Chassagne-Clément C, Beurrier F, Fondrevelle ME, Guérin N, Lasset C, Treilleux I.

Am J Surg. 2014 Aug;208(2):260-7. doi: 10.1016/j.amjsurg.2013.10.029. Epub 2014 Jan 23.

PMID:
24680949
35.

The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors.

Cassier PA, Floquet A, Penel N, Derbel O, Bui N'guyen B, Guastalla JP, Pissaloux D, Treilleux I, Saba CE, Blay JY, Ray-Coquard I.

Ann Oncol. 2014 May;25(5):1074-5. doi: 10.1093/annonc/mdu045. Epub 2014 Mar 20. No abstract available.

PMID:
24651409
36.

LKB1 when associated with methylatedERα is a marker of bad prognosis in breast cancer.

Bouchekioua-Bouzaghou K, Poulard C, Rambaud J, Lavergne E, Hussein N, Billaud M, Bachelot T, Chabaud S, Mader S, Dayan G, Treilleux I, Corbo L, Le Romancer M.

Int J Cancer. 2014 Sep 15;135(6):1307-18. doi: 10.1002/ijc.28781. Epub 2014 Mar 4.

37.

[Spontaneous regression of breast cancer after biopsy. About two cases].

Maillet L, Chopin N, Treilleux I, Bachelot T, Tredan O, Faure C, Caux C, Beurrier F.

Gynecol Obstet Fertil. 2014 Apr;42(4):269-72. doi: 10.1016/j.gyobfe.2013.08.017. Epub 2014 Jan 3. French.

PMID:
24394327
38.

Combining chemotherapeutic agents and netrin-1 interference potentiates cancer cell death.

Paradisi A, Creveaux M, Gibert B, Devailly G, Redoulez E, Neves D, Cleyssac E, Treilleux I, Klein C, Niederfellner G, Cassier PA, Bernet A, Mehlen P.

EMBO Mol Med. 2013 Dec;5(12):1821-34. doi: 10.1002/emmm.201302654. Epub 2013 Oct 8.

39.

Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO network.

Maillet D, Goulvent T, Rimokh R, Vacher-Lavenu MC, Pautier P, Alexandre J, Pujade-Laurraine E, Devouassoux-Shisheboran M, Treilleux I, Ray-Coquard I, Savina A.

Gynecol Oncol. 2014 Jan;132(1):181-7. doi: 10.1016/j.ygyno.2013.10.013. Epub 2013 Oct 22.

PMID:
24157616
40.

Semaphorin 3E suppresses tumor cell death triggered by the plexin D1 dependence receptor in metastatic breast cancers.

Luchino J, Hocine M, Amoureux MC, Gibert B, Bernet A, Royet A, Treilleux I, Lécine P, Borg JP, Mehlen P, Chauvet S, Mann F.

Cancer Cell. 2013 Nov 11;24(5):673-85. doi: 10.1016/j.ccr.2013.09.010. Epub 2013 Oct 17.

41.

Lysyl oxidase activity regulates oncogenic stress response and tumorigenesis.

Wiel C, Augert A, Vincent DF, Gitenay D, Vindrieux D, Le Calvé B, Arfi V, Lallet-Daher H, Reynaud C, Treilleux I, Bartholin L, Lelievre E, Bernard D.

Cell Death Dis. 2013 Oct 10;4:e855. doi: 10.1038/cddis.2013.382.

42.

TIF1γ requires sumoylation to exert its repressive activity on TGFβ signaling.

Fattet L, Ay AS, Bonneau B, Jallades L, Mikaelian I, Treilleux I, Gillet G, Hesling C, Rimokh R.

J Cell Sci. 2013 Aug 15;126(Pt 16):3713-23. doi: 10.1242/jcs.126748. Epub 2013 Jun 20.

43.

Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment.

Le Mercier I, Poujol D, Sanlaville A, Sisirak V, Gobert M, Durand I, Dubois B, Treilleux I, Marvel J, Vlach J, Blay JY, Bendriss-Vermare N, Caux C, Puisieux I, Goutagny N.

Cancer Res. 2013 Aug 1;73(15):4629-40. doi: 10.1158/0008-5472.CAN-12-3058. Epub 2013 May 30.

44.

The conditional expression of KRAS G12D in mouse pancreas induces disorganization of endocrine islets prior the onset of ductal pre-cancerous lesions.

Gout J, Pommier RM, Vincent DF, Ripoche D, Goddard-Léon S, Colombe A, Treilleux I, Valcourt U, Tomasini R, Dufresne M, Bertolino P, Bartholin L.

Pancreatology. 2013 May-Jun;13(3):191-5. doi: 10.1016/j.pan.2013.02.001. Epub 2013 Feb 18.

PMID:
23719586
45.

Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.

Vilquin P, Villedieu M, Grisard E, Ben Larbi S, Ghayad SE, Heudel PE, Bachelot T, Corbo L, Treilleux I, Vendrell JA, Cohen PA.

Int J Cancer. 2013 Oct 1;133(7):1589-602. doi: 10.1002/ijc.28182. Epub 2013 May 2.

46.

Breast cancer-derived transforming growth factor-β and tumor necrosis factor-α compromise interferon-α production by tumor-associated plasmacytoid dendritic cells.

Sisirak V, Vey N, Goutagny N, Renaudineau S, Malfroy M, Thys S, Treilleux I, Labidi-Galy SI, Bachelot T, Dezutter-Dambuyant C, Ménétrier-Caux C, Blay JY, Caux C, Bendriss-Vermare N.

Int J Cancer. 2013 Aug 1;133(3):771-8. doi: 10.1002/ijc.28072. Epub 2013 Mar 8.

47.

Primary ovarian borderline tumor in the inguinal lymph node.

Carrabin N, Treilleux I, Meeus P, Tredan O, Ray-Coquard I.

Int J Gynecol Pathol. 2013 Mar;32(2):167-70. doi: 10.1097/PGP.0b013e318257def6.

PMID:
23370643
48.

Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study.

Trédan O, Treilleux I, Wang Q, Gane N, Pissaloux D, Bonnin N, Petit T, Cretin J, Bonichon-Lamichhane N, Priou F, Lavau-Denes S, Mari V, Freyer G, Lebrun D, Alexandre J, Ray-Coquard I.

Target Oncol. 2013 Dec;8(4):243-51. doi: 10.1007/s11523-012-0242-9. Epub 2012 Dec 13.

PMID:
23238879
49.

High incidence of mammary intraepithelial neoplasia development in Men1-disrupted murine mammary glands.

Seigne C, Auret M, Treilleux I, Bonnavion R, Assade F, Carreira C, Goddard-Léon S, Lavergne E, Chabaud S, Garcia A, Mazoyer S, Lu J, Bachelot T, Frappart L, Zhang CX.

J Pathol. 2013 Mar;229(4):546-58. doi: 10.1002/path.4146.

PMID:
23180448
50.

Tif1γ is essential for the terminal differentiation of mammary alveolar epithelial cells and for lactation through SMAD4 inhibition.

Hesling C, Lopez J, Fattet L, Gonzalo P, Treilleux I, Blanchard D, Losson R, Goffin V, Pigat N, Puisieux A, Mikaelian I, Gillet G, Rimokh R.

Development. 2013 Jan 1;140(1):167-75. doi: 10.1242/dev.085068. Epub 2012 Nov 15.

Supplemental Content

Loading ...
Support Center